QIAGEN issues $750 million convertible bonds due 2032

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the placement of $750 million in senior, unsecured net share settled convertible bonds due 2032, according to a company statement.

The bonds will be issued at par and carry a 2.0% annual coupon, payable semi-annually. The initial conversion price will be set at a 40% premium over the reference share price, which equals the volume weighted average price of QIAGEN shares on the New York Stock Exchange on August 28, 2025.

The bonds may be converted in part into ordinary shares of QIAGEN and will be redeemed at par at maturity unless previously converted, redeemed or repurchased and cancelled. Final terms will be announced following determination of the reference share price after the close of trading on August 28, 2025.

In connection with the offering, QIAGEN agreed to a 90-day lock-up period following the settlement date, during which it will not sell securities substantially similar to the bonds or its shares, subject to certain exceptions and waiver by joint global coordinators.

The Netherlands-based company develops sample-to-insight solutions for extracting and analyzing molecular information from biological samples. QIAGEN serves more than 500,000 customers worldwide in life sciences and molecular diagnostics markets and employed approximately 5,700 people across more than 35 locations as of June 30, 2025.

The bonds have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.

You May Also Be Interested In